SG11202011927TA - Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease - Google Patents
Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory diseaseInfo
- Publication number
- SG11202011927TA SG11202011927TA SG11202011927TA SG11202011927TA SG11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA SG 11202011927T A SG11202011927T A SG 11202011927TA
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- stem cells
- mesenchymal stem
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862680748P | 2018-06-05 | 2018-06-05 | |
PCT/KR2019/006817 WO2019235854A1 (en) | 2018-06-05 | 2019-06-05 | Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202011927TA true SG11202011927TA (en) | 2020-12-30 |
Family
ID=68769796
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012124PA SG11202012124PA (en) | 2018-06-05 | 2019-06-05 | Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease |
SG11202011927TA SG11202011927TA (en) | 2018-06-05 | 2019-06-05 | Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012124PA SG11202012124PA (en) | 2018-06-05 | 2019-06-05 | Pharmaceutical composition comprising hyaluronic acid and stem cells for treating cartilage damage-associated disease |
Country Status (9)
Country | Link |
---|---|
US (2) | US20210228637A1 (en) |
EP (2) | EP3811951A4 (en) |
JP (2) | JP7343091B2 (en) |
KR (2) | KR20210008101A (en) |
CN (2) | CN112261943A (en) |
AU (2) | AU2019283518A1 (en) |
CA (2) | CA3100466A1 (en) |
SG (2) | SG11202012124PA (en) |
WO (2) | WO2019235853A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220152137A (en) | 2021-05-07 | 2022-11-15 | 의료법인 성광의료재단 | A mesenchymal stem cell with enhanced osteogenic differentiation capacity and an use thereof |
CN113616675A (en) * | 2021-08-23 | 2021-11-09 | 上海太安堂生物医学有限公司 | Composition containing mesenchymal stem cells and application thereof in treating degenerative arthritis |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003015802A1 (en) * | 2001-08-14 | 2003-02-27 | Medipost, Co., Ltd. | Composition for treatment of articular cartilage damage |
AU2004242091C1 (en) * | 2003-05-07 | 2009-12-24 | La Jolla Institute For Molecular Medicine | Administration of hyaluronic acid to enhance the function of transplanted stem cells |
EP2298863B1 (en) | 2004-03-22 | 2015-07-22 | Mesoblast International Sàrl | Mesenchymal stem cells and uses therefor |
JP5048323B2 (en) | 2004-03-31 | 2012-10-17 | 株式会社ツーセル | Therapeutic agent and treatment method for damaged tissue |
US8444968B2 (en) * | 2005-12-07 | 2013-05-21 | Isto Technologies, Inc. | Cartilage repair methods |
US20070178073A1 (en) * | 2006-02-01 | 2007-08-02 | Samsung Life Public Welfare Foundation | Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease |
NZ612888A (en) * | 2007-02-12 | 2015-02-27 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
EP2164505B1 (en) * | 2007-05-28 | 2014-09-17 | Monash University | Treatment of chronic lung disease |
EP2257289B1 (en) * | 2008-02-15 | 2018-09-19 | Bone Therapeutics | Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases |
CN103263440A (en) * | 2013-02-08 | 2013-08-28 | 周胜利 | Method for extracting and preparing homology mesenchymal stem cell injection from placenta and umbilical cord |
US20160184364A1 (en) * | 2013-08-14 | 2016-06-30 | Stempeutics Research Pvt. Ltd. | Management of osteoarthritis using pooled allogeneic mesenchymal stem cells |
JP6173157B2 (en) | 2013-10-02 | 2017-08-02 | 日本製薬株式会社 | IL-17 production inhibiting composition |
US20170166869A1 (en) * | 2014-02-04 | 2017-06-15 | Jose Javier Lopez GONZALEZ | Biologically optimized adult mesenchymal stem cells |
GB201410504D0 (en) * | 2014-06-12 | 2014-07-30 | Cell Therapy Ltd | Immuno-modulaltory progenitor (IMP) cell |
BR112016030758B8 (en) | 2014-06-30 | 2022-10-25 | Tigenix S A U | USE OF MULTIPOTENT STROME CELLS DERIVED FROM MESENCHYMAL ADIPOSE TISSUE |
KR101779763B1 (en) * | 2015-03-04 | 2017-09-19 | 메디포스트(주) | Pharmaceutical composition for the prevention or treatment of a lung disease comprising mesenchymal stem cells having improved proliferation and differentiation capacity |
JP6811724B2 (en) | 2015-04-24 | 2021-01-13 | ティジェニクス エス.エー.ユー. | Biomarkers to determine clinical response to cell therapy |
CN104840486A (en) * | 2015-04-30 | 2015-08-19 | 北京益诺勤生物技术有限公司 | Composition, application thereof and preparation |
HUP1500218A2 (en) * | 2015-05-08 | 2016-11-28 | Deltabio 2000 Kft | Method and composition for treatment of orthopedic diseases articular cortilage injuries and particularly to dysphoria |
EP3097922A1 (en) | 2015-05-28 | 2016-11-30 | Denis Barritault | Composition for the treatment of tissue lesions |
AU2017225902B2 (en) | 2016-02-29 | 2022-12-22 | Magellan Stem Cells Pty Ltd | Methods of treatment |
CN105796600B (en) * | 2016-04-28 | 2020-02-28 | 博雅干细胞科技有限公司 | Methods and compositions for treating osteoarthritis using stem cells |
US20180021380A1 (en) * | 2016-07-21 | 2018-01-25 | Sungkwang Medical Foundation | Composition including mesenchymal stem cell derived from adipose tissues and hyaluronic acid derivative, method of preparing the same, and method of preventing or treating low back pain using the same |
JP7179723B2 (en) * | 2016-10-24 | 2022-11-29 | ユナイテッド セラピューティクス コーポレイション | Enhancing the Immunomodulatory Properties of MSCs by Treprostinil |
MX2019005127A (en) * | 2016-11-03 | 2019-09-26 | Exostem Biotec Ltd | Mesenchymal stem cells populations, their products, and use thereof. |
CN111518758A (en) * | 2020-04-30 | 2020-08-11 | 深圳市合一康生物科技股份有限公司 | Umbilical cord mesenchymal stem cells for treating lung diseases and preparation method thereof |
CN113018317A (en) * | 2021-02-03 | 2021-06-25 | 上海兰天生物医药科技有限公司 | Application of mesenchymal stem cells and sodium hyaluronate in treatment of arthritis |
-
2019
- 2019-06-05 AU AU2019283518A patent/AU2019283518A1/en active Pending
- 2019-06-05 US US16/972,373 patent/US20210228637A1/en active Pending
- 2019-06-05 JP JP2020564727A patent/JP7343091B2/en active Active
- 2019-06-05 CA CA3100466A patent/CA3100466A1/en active Pending
- 2019-06-05 EP EP19814590.6A patent/EP3811951A4/en active Pending
- 2019-06-05 CN CN201980038809.4A patent/CN112261943A/en active Pending
- 2019-06-05 JP JP2020564579A patent/JP7480454B2/en active Active
- 2019-06-05 SG SG11202012124PA patent/SG11202012124PA/en unknown
- 2019-06-05 WO PCT/KR2019/006816 patent/WO2019235853A1/en unknown
- 2019-06-05 KR KR1020207036315A patent/KR20210008101A/en not_active Application Discontinuation
- 2019-06-05 EP EP19815851.1A patent/EP3804736A4/en active Pending
- 2019-06-05 SG SG11202011927TA patent/SG11202011927TA/en unknown
- 2019-06-05 AU AU2019283517A patent/AU2019283517A1/en active Pending
- 2019-06-05 CA CA3100471A patent/CA3100471A1/en active Pending
- 2019-06-05 WO PCT/KR2019/006817 patent/WO2019235854A1/en unknown
- 2019-06-05 KR KR1020207036318A patent/KR20210008873A/en not_active Application Discontinuation
- 2019-06-05 CN CN201980038790.3A patent/CN112261944A/en active Pending
- 2019-06-05 US US16/972,118 patent/US20210228636A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210008101A (en) | 2021-01-20 |
SG11202012124PA (en) | 2021-01-28 |
US20210228636A1 (en) | 2021-07-29 |
CA3100471A1 (en) | 2019-12-12 |
CA3100466A1 (en) | 2019-12-12 |
KR20210008873A (en) | 2021-01-25 |
US20210228637A1 (en) | 2021-07-29 |
JP7343091B2 (en) | 2023-09-12 |
JP2021526135A (en) | 2021-09-30 |
WO2019235854A1 (en) | 2019-12-12 |
CN112261944A (en) | 2021-01-22 |
WO2019235853A1 (en) | 2019-12-12 |
EP3804736A1 (en) | 2021-04-14 |
CN112261943A (en) | 2021-01-22 |
AU2019283518A1 (en) | 2021-01-14 |
AU2019283517A1 (en) | 2021-01-21 |
EP3811951A4 (en) | 2022-07-13 |
EP3811951A1 (en) | 2021-04-28 |
JP7480454B2 (en) | 2024-05-10 |
JP2021526137A (en) | 2021-09-30 |
EP3804736A4 (en) | 2022-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
SG11202106160WA (en) | Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient | |
IL288375A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
EP3586853A4 (en) | Pharmaceutical composition comprising inflammation-stimulated mesenchymal stem cell for prevention or treatment of immune disease or inflammatory disease | |
IL279397A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
ZA202002166B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
IL286677A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
GB201911868D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
IL286688A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
IL257336B (en) | Compounds and pharmaceutical compositions for prevention or treatment of parasitic diseases | |
MX2021003643A (en) | Terpinoid derivatives and uses thereof. | |
SG11202011927TA (en) | Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease | |
EP3643302C0 (en) | Composition containing sesquiterpene derivative as active ingredient for prevention or treatment of muscle diseases | |
SG11202106163RA (en) | Pharmaceutical composition for prevention or treatment of cancer comprising lactobacillus sakei wikim30 as active ingredient | |
EP3603656A4 (en) | Pharmaceutical composition for prevention or treatment of gynecological diseases containing extract of sarcodon imbricatus as active ingredient | |
IL285751A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
IL286685A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | |
EP3795170C0 (en) | Pharmaceutical composition comprising ccn5 as active ingredient for preventing or treating retinal diseases | |
HUE053866T2 (en) | Pharmaceutical composition for the treatment of constipation | |
EP3903803A4 (en) | Pharmaceutical composition comprising pibf protein as active ingredient for prevention or treatment of inflammatory disease | |
EP3187179A4 (en) | Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient | |
GB201817344D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
GB201817343D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
GB201809836D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases |